YU86501A - Derivati etansulfonil-piperidina - Google Patents

Derivati etansulfonil-piperidina

Info

Publication number
YU86501A
YU86501A YU86501A YUP86501A YU86501A YU 86501 A YU86501 A YU 86501A YU 86501 A YU86501 A YU 86501A YU P86501 A YUP86501 A YU P86501A YU 86501 A YU86501 A YU 86501A
Authority
YU
Yugoslavia
Prior art keywords
disease
neurodegeneration
compounds
chronic
denotes
Prior art date
Application number
YU86501A
Other languages
English (en)
Inventor
Alexander Alanine
Serge Burner
Bernd Buttelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of YU86501A publication Critical patent/YU86501A/sh
Publication of RS50033B publication Critical patent/RS50033B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Abstract

Ovaj pronalazak se odnosi na jedinjenja opšte formule (I) u kojoj R1 označava vodonik ili hidroksi, R2 označava vodonik ili metil i X označava -O- ili -CH2-, i njihove farmaceutski prihvatljive kiselinske adicione soli. Pokazano je da ova jedinjenja imaju dobar afinitet prema NMDA receptoru i otuda su prikladna u lečenju bolesti, pri čemu ove terapeutske indikacije uključuju akutne oblike neurodegeneracije koji su prouzrokovani, npr., moždanim udarom ili moždanom traumom, hronične oblike neurodegeneracije kao što su Alchajmerova bolest, Parkinsonova bolest, Hantingtonova bolest ili ALS (amiotrofična lateralna skleroza), neurodegeneracije koja je u vezi sa bakterijskim ili virusnim infekcijama, i bolesti kao što su shizofrenija, brižnost (anksioznost), depresija i hronični/akutni bol.
YUP-865/01A 1999-06-08 2000-05-31 Derivati etansulfonil-piperidina RS50033B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08

Publications (2)

Publication Number Publication Date
YU86501A true YU86501A (sh) 2004-09-03
RS50033B RS50033B (sr) 2008-11-28

Family

ID=8238316

Country Status (38)

Country Link
US (1) US6310213B1 (sh)
EP (1) EP1189886B1 (sh)
JP (1) JP3645856B2 (sh)
KR (1) KR100571162B1 (sh)
CN (1) CN1142141C (sh)
AR (1) AR024282A1 (sh)
AT (1) ATE315025T1 (sh)
AU (1) AU770787B2 (sh)
BR (1) BR0011419A (sh)
CA (1) CA2376091C (sh)
CO (1) CO5160328A1 (sh)
CZ (1) CZ299483B6 (sh)
DE (1) DE60025348T2 (sh)
DK (1) DK1189886T3 (sh)
EG (1) EG26101A (sh)
ES (1) ES2254183T3 (sh)
GC (1) GC0000256A (sh)
GT (1) GT200000089A (sh)
HK (1) HK1046412B (sh)
HR (1) HRP20010885B1 (sh)
HU (1) HU228591B1 (sh)
IL (2) IL146750A0 (sh)
JO (1) JO2260B1 (sh)
MA (1) MA26797A1 (sh)
MX (1) MXPA01012585A (sh)
MY (1) MY128818A (sh)
NO (1) NO320613B1 (sh)
PA (1) PA8496601A1 (sh)
PE (1) PE20010218A1 (sh)
PL (1) PL196053B1 (sh)
RS (1) RS50033B (sh)
RU (1) RU2242464C2 (sh)
SI (1) SI1189886T1 (sh)
TN (1) TNSN00125A1 (sh)
TR (1) TR200103532T2 (sh)
TW (1) TWI254043B (sh)
WO (1) WO2000075109A1 (sh)
ZA (1) ZA200109706B (sh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1136475T3 (da) 2000-03-22 2004-12-27 Hoffmann La Roche Piperidin- og piperazinderivater til anvendelse i behandlingen af Alzheimer
EP1278728B1 (en) * 2000-04-20 2004-08-25 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
US20050260577A1 (en) * 2000-10-09 2005-11-24 Kay Double Detection of neurodegenerative disorders
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
CN103917096A (zh) * 2011-07-18 2014-07-09 阿得罗公司 外周阿片样物质拮抗剂化合物的制备方法及所述化合物的中间体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
EP1189886A1 (en) 2002-03-27
DE60025348T2 (de) 2006-08-24
HRP20010885B1 (en) 2010-07-31
SI1189886T1 (sl) 2006-04-30
AU770787B2 (en) 2004-03-04
IL146750A (en) 2006-12-10
GT200000089A (es) 2001-11-29
NO320613B1 (no) 2005-12-27
MXPA01012585A (es) 2002-04-10
AR024282A1 (es) 2002-09-25
GC0000256A (en) 2006-11-01
RU2242464C2 (ru) 2004-12-20
RS50033B (sr) 2008-11-28
TNSN00125A1 (fr) 2005-11-10
EP1189886B1 (en) 2006-01-04
WO2000075109A1 (en) 2000-12-14
HU228591B1 (hu) 2013-04-29
MY128818A (en) 2007-02-28
US6310213B1 (en) 2001-10-30
HK1046412A1 (en) 2003-01-10
HRP20010885A2 (en) 2004-02-29
CO5160328A1 (es) 2002-05-30
DE60025348D1 (de) 2006-03-30
PE20010218A1 (es) 2001-02-28
JO2260B1 (en) 2004-10-07
NO20015920L (no) 2001-12-04
HUP0201916A3 (en) 2003-05-28
JP2003501415A (ja) 2003-01-14
PL196053B1 (pl) 2007-11-30
KR100571162B1 (ko) 2006-04-17
HK1046412B (zh) 2004-07-09
CN1142141C (zh) 2004-03-17
CA2376091C (en) 2006-03-14
ES2254183T3 (es) 2006-06-16
MA26797A1 (fr) 2004-12-20
ZA200109706B (en) 2003-02-26
DK1189886T3 (da) 2006-05-15
CN1354745A (zh) 2002-06-19
EG26101A (en) 2013-02-17
NO20015920D0 (no) 2001-12-04
TWI254043B (en) 2006-05-01
CZ299483B6 (cs) 2008-08-13
TR200103532T2 (tr) 2002-05-21
KR20020008850A (ko) 2002-01-31
CZ20014349A3 (cs) 2002-05-15
HUP0201916A2 (en) 2002-10-28
BR0011419A (pt) 2002-02-26
PL352723A1 (en) 2003-09-08
ATE315025T1 (de) 2006-02-15
AU5218100A (en) 2000-12-28
CA2376091A1 (en) 2000-12-14
PA8496601A1 (es) 2001-12-14
IL146750A0 (en) 2002-07-25
JP3645856B2 (ja) 2005-05-11

Similar Documents

Publication Publication Date Title
MEP76708A (en) (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
CA2407345A1 (en) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
DK1267866T3 (da) Behandling af respirationssygdomme
BR0206955A (pt) Ligantes de receptores de canabinóides
BR0212185A (pt) Compostos e métodos para a preparação de compostos
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
YU86501A (sh) Derivati etansulfonil-piperidina
BR0210028A (pt) Agentes antibacterianos
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
BR9801157A (pt) Derivados de adamantano substituìdos por flúor.
CA2126118A1 (en) 5-Amino-8-Methyl-7-Pyrrolidinylquinoline-3-Carboxylic Acid Derivative
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
AR037249A1 (es) Compuestos derivados de piridina, un procedimiento para prepararlos y medicamentos que los contienen
HRP20110595T1 (hr) Deglikozilirani i desijalidirani dugi pentraksin ptx3
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
BR0112609A (pt) Derivados de anilina
CA2431761A1 (en) Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
ECSP003519A (es) Derivados de etanosulfonilo-piperidina
YU48296A (sh) Polimorfni oblici proleka 6-n(l-ala-l-ala)-trovafloksacina, postupci za dobijanje i njihove farmaceutske kompozicije
BRPI0413545A (pt) composições farmacêuticas
BR9815690A (pt) Composto, processo para a preparação de qualquer um dos compostos, composição farmacêutica, e, uso do composto de 3-(nafter-1-il-óxi) - pirrolidina, 3-(5,6,7,8 - tetraidro-nafterc-1-il-óxi) - pirrolindina
ITMI981691A0 (it) Composizioni farmaceutiche atte alla sommistrazione per via transder male di apomorfina